Triton Market Research, in its report on the CRISPR market in the Asia-Pacific region, has determined that the market is expected to expand at a CAGR of 25.67% during the forecasted years 2019-2028.
The countries studied in the Asia-Pacific CRISPR market are:
• South Korea
• China
• ASEAN countries
• Japan
• India
• Australia & New Zealand
• Rest of APAC countries
In China, scientists have already used CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats) to modify human embryos, clone a dog and splice genes in mice and monkeys. Few American biotechnological firms have been exporting CRISPR technology for scientific discovery across the world. These companies are focusing customers, particularly in China, as the country is conducting civilian research work and development work of sinister military applications using this technique. Extensive gene-editing research is being carried out in China, with difficulty in determining whether this research work falls under civilian, defense or military segments. Institutions similar to DARPA (Defense Advanced Research Projects Agency) in the US, handle medical studies and are rigorously pumping out research for CRISPR.
It is reported that the military scientists in China are using the CRISPR technique to generate proteins of human blood, named albumin, in baby pigs. They are also working on Hepatitis-B virus DNA with CRISPR. These researchers are enhancing the CRISPR gene-splicing technique with light-induced systems. Studies are also focusing on improving cancer drug resistance with the help of CRISPR. These developments in the country are likely to instigate the demand for the CRISPR market, thereby increasing the market growth in the coming period.
Established in 1897, Lonza is a Switzerland-based chemical and biotechnology company. The company produces fine organic chemicals, active ingredients, biocides and biotechnology products. It offers its products to the pharmaceutical, academic, biotechnology and government research sectors through manufacturers, consumers, distributors and service companies. The company operates in different regions, including the Asia-Pacific.
Some of the key companies in the CRISPR market are Intellia Therapeutics Inc, Cellectis, Sigma-Aldrich (Merck KGaA), GenScript, New England Biolabs, GeneCopoeia Inc, Origene Technologies Inc, Addgene, Horizon Discovery Ltd, Applied StemCell, Thermo Fisher Scientific Inc, Editas Medicine, DiaCarta, Caribou Biosciences Inc, Sangamo Therapeutics, Transposagen Bio (Hera BioLabs), Genedata AG, Precision Biosciences, Lonza, Integrated DNA Technologies Inc and CRISPR Therapeutics.